However, high expression of CD90 in the CSCs of various cancers, including liver cancer, could be a reason to target CD90+ cancer cells by CAR T cells; unfortunately, no studies using anti-CD90 CAR T cell as a potential treatment for cancer have been reported. This evidence concerns the gene THY1 and liver cancer.